Pharmafile Logo

News and Press Releases

Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases

Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026

Immuthera
office@immuthera.bio

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 8, 2026

Allogene Therapeutics
210 E. Grand Avenue South San Francisco, CA 94080

Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates

Novel approach harnessing the power of the complement system to drive potent cell depletion Single-dose study shows rapid and sustained immune cell depletion in blood and tissues with a very...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 11, 2025

Commit Biologics
info@commitbio.com
Universitetsbyen 83 8000 Aarhus C, Denmark

New Anthem from Girl Band Raises Awareness of Type1 Diabetes After Research Highlights Silent Struggle

Recent research from Sanofi highlights the significant impact of Type 1 Diabetes on those living with the condition The song, “Rise Up,” shares their experiences of living with the condition...

Category: Other, Pharmaceutical
Posted: May 29, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025

Alys Pharmaceuticals
info@alyspharma.com
100 Northern Avenue Boston Massachusetts 02210, United States

UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)

28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 28, 2024

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating the Company’s Lead Development Program SR-878

Transition into clinical-stage development marks a significant corporate and R&D milestone 17 October 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic iRhom2...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 17, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

SciRhom Secures €63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases

The upsized and oversubscribed Series A financing round will be used to drive the lead development programme toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2...

Category: Drug Discovery, Other, Pharmaceutical
Posted: July 9, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

SciRhom
info@SciRhom.com
Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Calypso Enters into Agreement to Be Acquired by Novartis

Calypso is a European biotech translating Interleukin-15 biology into medical breakthroughs by developing CALY-002, an anti-IL-15 monoclonal antibody, for an array of autoimmune indications The acquisition of Calypso gives Novartis...

Category: Biotechnology
Posted: January 8, 2024

Calypso Biotech
Gustav Mahlerplein 102 1082 MA Amsterdam The Netherlands